论文部分内容阅读
RGD肽是含有精氨酸-甘氨酸-门冬氨酸(Arg-Gly-Asp)序列的一类短肽,能和细胞表面的整合素受体特异性结合。整合素受体,尤其是v 3高表达于脑胶质瘤等肿瘤细胞表面,而在成熟血管内皮细胞呈低表达。因此,在脑胶质瘤的靶向治疗和显像研究中外源性RGD肽与肿瘤细胞表面的整合素受体的竞争性结合得到广泛研究。本文综述了RGD肽介导的脑胶质瘤靶向治疗及显像的典型方法及近年来的研究进展。
RGD peptide is a kind of short peptide containing arginine-glycine-aspartic acid (Arg-Gly-Asp) sequence, which can specifically bind to cell surface integrin receptors. Integrin receptors, especially v 3, are highly expressed on the surface of glioma and other tumor cells, but are low on mature vascular endothelial cells. Thus, the competitive binding of exogenous RGD peptides to integrin receptors on the surface of tumor cells has been extensively studied in targeted therapy and imaging studies of gliomas. This review summarizes the RGD peptide-mediated targeted therapy and imaging of glioma typical methods and research progress in recent years.